News

404

Theresa Visarius, Ph.D.

Theresa Visarius, Ph.D.

VP INTERNATIONAL BUSINESS DEVELOPMENT
MANAGING DIRECTOR - IPS BIOPHARMA AG (Swiss Subsidiary)

Dr. Visarius is the Vice President of Business Development at Immunophotonics and Managing Director of the Swiss subsidiary IPS Biopharma AG. She joined the company in 2015 after 8 years as an entrepreneur where she worked with global leaders in health care as well as start-ups to facilitate market access of innovative medical technologies.
Theresa received her PhD in Pharmacology from the University of Bern, Switzerland and holds degrees is biology and chemistry from the USA. She has conducted research in clinical pharmacology, mitochondrial bioenergetics, and molecular toxicology, with a focus on cancer research and clinical pharmacology. Her doctoral work identified the mitochondrial mechanism underlying the neuroprotective action of methylene blue to prevent or reverse encephalopathy associated with ifosfamide chemotherapy.
At Immunophotonics and IPS Biopharma, Theresa combines a strong scientific foundation with a passion for game-changing innovation that can lead to impactful patient benefit.

VP INTERNATIONAL BUSINESS DEVELOPMENT
MANAGING DIRECTOR - IPS BIOPHARMA AG (Swiss Subsidiary)

Dr. Visarius is the Vice President of Business Development at Immunophotonics and Managing Director of the Swiss subsidiary IPS Biopharma AG. She joined the company in 2015 after 8 years as an entrepreneur where she worked with global leaders in health care as well as start-ups to facilitate market access of innovative medical technologies.
Theresa received her PhD in Pharmacology from the University of Bern, Switzerland and holds degrees is biology and chemistry from the USA. She has conducted research in clinical pharmacology, mitochondrial bioenergetics, and molecular toxicology, with a focus on cancer research and clinical pharmacology. Her doctoral work identified the mitochondrial mechanism underlying the neuroprotective action of methylene blue to prevent or reverse encephalopathy associated with ifosfamide chemotherapy.
At Immunophotonics and IPS Biopharma, Theresa combines a strong scientific foundation with a passion for game-changing innovation that can lead to impactful patient benefit.

Scroll to top